Recombinant Anti-BRAF (phospho S729) antibody [EPR2207] (ab124794)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2207] to BRAF (phospho S729)
- Suitable for: WB
- Reacts with: Rat
Related conjugates and formulations
Overview
-
Product name
Anti-BRAF (phospho S729) antibody [EPR2207]
See all BRAF primary antibodies -
Description
Rabbit monoclonal [EPR2207] to BRAF (phospho S729) -
Host species
Rabbit -
Specificity
Detects B Raf only when phosphorylated on serine 729. -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IP -
Species reactivity
Reacts with: Rat
Predicted to work with: Mouse, Human -
Immunogen
Synthetic peptide corresponding to Human BRAF.
-
Positive control
- PC-12 cell lysates
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Dissociation constant (KD)
KD = 9.00 x 10 -12 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2207 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab124794 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 84 kDa.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 84 kDa. |
Target
-
Function
Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. -
Tissue specificity
Brain and testis. -
Involvement in disease
Note=Defects in BRAF are found in a wide range of cancers.
Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500].
Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980].
Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation. -
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 protein kinase domain.
Contains 1 RBD (Ras-binding) domain. -
Cellular localization
Nucleus. Cytoplasm. Cell membrane. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes. - Information by UniProt
-
Database links
- Entrez Gene: 673 Human
- Entrez Gene: 109880 Mouse
- Entrez Gene: 114486 Rat
- Omim: 164757 Human
- SwissProt: P15056 Human
- SwissProt: P28028 Mouse
- Unigene: 550061 Human
- Unigene: 245513 Mouse
-
Alternative names
- FLJ95109 antibody
- 94 kDa B raf protein antibody
- B raf 1 antibody
see all
Images
-
All lanes : Anti-BRAF (phospho S729) antibody [EPR2207] (ab124794) at 1/1000 dilution
Lane 1 : PC-12 cell lysates (untreated)
Lane 2 : PC-12 cell lysates treated with Lambda Phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 84 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab124794 has been referenced in 8 publications.
- Oberoi J et al. HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation. Nat Commun 13:7343 (2022). PubMed: 36446791
- Cope NJ et al. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. J Biol Chem 295:2407-2420 (2020). PubMed: 31929109
- Zhang Y et al. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B 9:294-303 (2019). PubMed: 30976491
- Wang X et al. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. Dev Cell 48:345-360.e7 (2019). PubMed: 30595535
- Fujita K et al. Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Nat Commun 9:433 (2018). PubMed: 29382817
- Vido MJ et al. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3 (2018). PubMed: 30404005
- Gantois I et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med 23:674-677 (2017). PubMed: 28504725
- Guo Y et al. Comprehensive Ex Vivo Transposon Mutagenesis Identifies Genes That Promote Growth Factor Independence and Leukemogenesis. Cancer Res 76:773-86 (2016). PubMed: 26676752